SecBot SecBot
8-K ·Filed Aug 4, 2026

FTH

Faeth Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed3mo ago SEC0001193125-26-331563
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor for topline Phase 2 data from the PIK-201 trial in endometrial cancer, expected by year-end 2026, which is the next major catalyst. The current cash runway supports operations through this readout.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$25.50
T+0 close · Aug 4, 2026 · via day close
Latest settled
−25.06%
T+60 · $19.11
Vs SPY
−25.43%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 4 $25.50entry
  2. T+1 · 3mo ago −3.57%α −3.37% · $24.59
  3. T+5 · 3mo ago +17.65%α +17.75% · $30.00
  4. T+20 · 3mo ago +35.33%α +36.57% · $34.51
  5. T+60 · 20d ago −25.06%α −25.43% · $19.11
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Faeth Therapeutics (FTH) reported Q2 2026 financial results with a net loss of $16.0M ($2.84/share), compared to a net loss of $4.9M ($3.91/share) in Q2 2025. The company highlighted that topline Phase 2 data for PIKTOR in endometrial cancer remains on track for year-end 2026, and the first patient was dosed in the Phase 1b/2 breast cancer trial. The company has $186.4M in cash and securities, providing runway through key milestones. The filing is a routine quarterly update for a clinical-stage biotech with no revenue and no consensus estimates provided for the current quarter, making it neutral with low impact.

Key Financial Metrics

EPS
−$2.84
Rating
in line

Key Facts

  • Net loss was $16.0M ($2.84/share) for Q2 2026 vs $4.9M ($3.91/share) in Q2 2025.
  • Cash, cash equivalents and marketable securities were $186.4M as of June 30, 2026.
  • Topline Phase 2 data for PIKTOR in endometrial cancer expected by year-end 2026.
  • First patient dosed in Phase 1b/2 trial of PIKTOR in HR+ breast cancer in April 2026.
  • Company changed name to Faeth Therapeutics and began trading under ticker FTH on June 16, 2026.
  • Stockholders approved conversion of Series B preferred stock into common stock in June 2026.

Financial Impact

Net loss increased to $16.0M from $4.9M YoY; cash position $186.4M provides runway through key clinical milestones.

net losscash position

Risk Factors

  • Clinical trial failure or disappointing data for PIKTOR.
  • Cash burn rate may require future financing before reaching profitability.

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-331563
Document: d168633d8k.htm0001193125-26-331563
Document: 0001193125-26-331563-index-headers.html0001193125-26-331563
Document: 0001193125-26-331563-index.html0001193125-26-331563
Document: 0001193125-26-331563.txt0001193125-26-331563
8-K Data (Synthetic)0001193125-26-331563

Track record

12 reports on FTH

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +35.00% at T+60 after the Aug 11, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $10.03 Now $9.28 −7.48% settles Nov 17
  3. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $12.68 to $12.92 Now $9.28 −26.81% ▲ +1.89% +2.26% vs SPY
  4. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $12.68 to $12.92 Now $9.28 −26.81% ▲ +1.89% +2.26% vs SPY
  5. Nov 3, 202613d ago 8-K Neutral 5/10 Entry $19.65 to $19.99 Now $9.28 −52.77% ▲ +1.73% +0.08% vs SPY
  6. Oct 27, 202620d ago 3 Neutral 2/10 Entry $19.20 to $18.75 Now $9.28 −51.67% ▼ −2.34% −1.96% vs SPY
  7. Oct 27, 202620d ago 8-K Neutral 2/10 Entry $19.11 to $19.20 Now $9.28 −51.44% ▲ +0.47% +0.13% vs SPY
  8. Sep 15, 20268w ago 3 Neutral 2/10 Entry $34.24 to $35.13 Now $9.28 −72.90% ▲ +2.60% +1.47% vs SPY
  9. Aug 11, 202613w ago 144 Bearish 5/10 Entry $30.00 to $29.38 Now $9.28 +69.07% ▲ +2.07% +2.32% vs SPY
  10. Aug 4, 202614w ago 8-K Neutral 3/10 Viewing Entry $25.50 to $24.59 Now $9.28 −63.61% ▼ −3.57% −3.37% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (14h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026